Gilead, Cognizant

Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
Cognizant Expands Partnership With Gilead Sciences To Enhance Efficiency And AI Integration
Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost
Cognizant expands AI services for Gilead Sciences
Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee engagement,
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases.
Cognizant, Gilead expand relationship
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
SourceSecurity1mon
Cognizant - Experts & Thought Leaders
Cognizant delivers a broad range of IT and cybersecurity services, including through a longstanding partnership with Gilead Sciences, Inc. “Cognizant has been a key service provider to Gilead ...
Courthouse News Service1y
Gilead must stand trial over defective HIV drug claims
The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead's drugs, which could have swapped out an ingredient for a safer alternative. OAKLAND, Calif. (CN) — The ...
pharmaphorum7y
Gilead swoops to buy Kite for $12billion
After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...
U.S. News & World Report15d
Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs
Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...
FiercePharma14d
Gilead's Kite taps longtime Amgen alum as new global commercial head
Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of global commercial, he announced on LinkedIn this week. “CAR T-cell therapy has changed ...
pharmaphorum5d
Gilead, MSD say HIV combo could be weekly, oral HIV drug
In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.